Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.
2.

[Methadone: from pharmacokinetic profile to clinical pharmacology].

Vazquez V, Gury C, Laqueille X.

Encephale. 2006 Jul-Aug;32(4 Pt 1):478-86. Review. French.

PMID:
17099560
3.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
4.
5.

Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.

Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F.

Br J Clin Pharmacol. 2000 Nov;50(5):427-40.

6.

Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment.

Eap CB, Bourquin M, Martin J, Spagnoli J, Livoti S, Powell K, Baumann P, Déglon J.

Drug Alcohol Depend. 2000 Dec 22;61(1):47-54.

PMID:
11064183
7.

Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate.

Boulton DW, Arnaud P, DeVane CL.

Clin Pharmacol Ther. 2001 Jul;70(1):48-57.

PMID:
11452244
8.

Interindividual variability of methadone response: impact of genetic polymorphism.

Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S.

Mol Diagn Ther. 2008;12(2):109-24. Review.

PMID:
18422375
9.

Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses.

Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB.

Drug Alcohol Depend. 2003 Mar 1;69(2):205-11.

PMID:
12609702
10.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
11.

ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.

Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Eap CB.

Clin Pharmacol Ther. 2006 Dec;80(6):668-81.

PMID:
17178267
12.

Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients.

Uehlinger C, Crettol S, Chassot P, Brocard M, Koeb L, Brawand-Amey M, Eap CB.

J Clin Psychopharmacol. 2007 Jun;27(3):273-8.

PMID:
17502774
13.

Clinical pharmacokinetics of nisoldipine coat-core.

Heinig R.

Clin Pharmacokinet. 1998 Sep;35(3):191-208. Review. Erratum in: Clin Pharmacokinet 1998 Nov;35(5):390.

PMID:
9784933
14.

When "enough" is not enough: new perspectives on optimal methadone maintenance dose.

Leavitt SB, Shinderman M, Maxwell S, Eap CB, Paris P.

Mt Sinai J Med. 2000 Oct-Nov;67(5-6):404-11. Review.

PMID:
11064491
15.

Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.

Lötsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmöller J, Geisslinger G.

Clin Pharmacol Ther. 2006 Jan;79(1):72-89.

PMID:
16413243
16.

Clinical pharmacokinetics of mirtazapine.

Timmer CJ, Sitsen JM, Delbressine LP.

Clin Pharmacokinet. 2000 Jun;38(6):461-74. Review.

PMID:
10885584
17.

Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment.

Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, Rostami-Hodjegan A.

J Clin Psychopharmacol. 2012 Oct;32(5):666-71. doi: 10.1097/JCP.0b013e3182664ecd.

PMID:
22926601
18.

Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.

Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S, Hendrix CW.

Pharmacotherapy. 2008 Jul;28(7):863-74. doi: 10.1592/phco.28.7.863.

PMID:
18576901
19.

Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

Foster DJ, Somogyi AA, White JM, Bochner F.

Br J Clin Pharmacol. 2004 Jun;57(6):742-55.

20.

Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4.

Foster DJ, Somogyi AA, Bochner F.

Br J Clin Pharmacol. 1999 Apr;47(4):403-12.

Items per page

Supplemental Content

Support Center